Drug Trial Radar · NCT05143463
A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion
Last checked: Nov 19, 2026Latest source record: Dec 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Nov 4, 2021
Primary completion
Aug 19, 2022
Study completion Dec 22, 2022
Sponsor
- Lead sponsor
- Neuracle Science Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Dec 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Up to 80 healthy adult males, ≥ 18 and ≤ 55 years of age, are planned to be enrolled in the study. The study will consist of 8 cohorts (Cohorts 1 to 8, 1 cohort per dose level). Each cohort will include 8 subjects (6 subjects receiving a single dose of the study drug NS101 and 2 subjects receiving a single dose of a matching placebo), for a total of 64 subjects planned for evaluation. A total of 21 blood samples will be collected in each cohort for PK analysis and a total of 14 blood samples will be collected in each cohort for PD analysis.
Conditions
- Neurodegenerative Diseases
Interventions
NS101 IV infusionDrug
Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AEs of NS101 following intravenous (IV) administration of single ascending doses in healthy subjectsTime frame: up to 60 Days ± 3 after IV infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Syneos Health
Québec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.